Imperial College London
Portrait Picture

DrHarryWhitwell

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Lecturer in Proteomics and Integrative Data Analysis Proteom
 
 
 
//

Contact

 

h.whitwell Website CV

 
 
//

Location

 

312Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cuenco:2018:10.18632/oncotarget.24732,
author = {Cuenco, J and Wehnert, N and Blyuss, O and Kazarian, A and Whitwell, HJ and Menon, U and Dawnay, A and Manns, MP and Pereira, SP and Timms, JF},
doi = {10.18632/oncotarget.24732},
journal = {Oncotarget},
pages = {17430--17442},
title = {Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholagnitis},
url = {http://dx.doi.org/10.18632/oncotarget.24732},
volume = {9},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The non-invasive differentiation of malignant and benign biliary disease is a clinical challenge. Carbohydrate antigen 19-9 (CA19-9), leucine-rich α2-glycoprotein (LRG1), interleukin 6 (IL6), pyruvate kinase M2 (PKM2), cytokeratin 19 fragment (CYFRA21.1) and mucin 5AC (MUC5AC) have reported utility for differentiating cholangiocarcinoma (CCA) from benign biliary disease. Herein, serum levels of these markers were tested in 66 cases of CCA and 62 cases of primary sclerosing cholangitis (PSC) and compared with markers of liver function and inflammation. Markers panels were assessed for their ability to discriminate malignant and benign disease. Several of the markers were also assessed in pre-diagnosis biliary tract cancer (BTC) samples with performances evaluated at different times prior to diagnosis. We show that LRG1 and IL6 were unable to accurately distinguish CCA from PSC, whereas CA19-9, PKM2, CYFRA21.1 and MUC5AC were significantly elevated in malignancy. Area under the receiver operating characteristic curves for these individual markers ranged from 0.73–0.84, with the best single marker (PKM2) providing 61% sensitivity at 90% specificity. A panel combining PKM2, CYFRA21.1 and MUC5AC gave 76% sensitivity at 90% specificity, which increased to 82% sensitivity by adding gamma-glutamyltransferase (GGT). In the pre-diagnosis setting, LRG1, IL6 and PKM2 were poor predictors of BTC, whilst CA19-9 and C-reactive protein were elevated up to 2 years before diagnosis. In conclusion, LRG1, IL6 and PKM2 were not useful for early detection of BTC, whilst a model combining PKM2, CYFRA21.1, MUC5AC and GGT was beneficial in differentiating malignant from benign biliary disease, warranting validation in a prospective trial.
AU  - Cuenco,J
AU  - Wehnert,N
AU  - Blyuss,O
AU  - Kazarian,A
AU  - Whitwell,HJ
AU  - Menon,U
AU  - Dawnay,A
AU  - Manns,MP
AU  - Pereira,SP
AU  - Timms,JF
DO  - 10.18632/oncotarget.24732
EP  - 17442
PY  - 2018///
SN  - 1949-2553
SP  - 17430
TI  - Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholagnitis
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.24732
UR  - http://hdl.handle.net/10044/1/59789
VL  - 9
ER  -
Download